Yale University’s Atara Biotherapeutics ATRA Stock Holding History

Yale University’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-370	Closed	-$291K	–	6
2015 Q3	$291K	Buy	+370	New	+$451K	0.09%	5

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

Bridger Management New York $150M AUM 17.71% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Yale University's ATRA Position: Q4 2015 in Review

Yale University sold out of Atara Biotherapeutics (ATRA) in Q4 2015, closing a stake of 370 shares — an estimated $291K sold.

Yale University first reported a position in ATRA in Q3 2015 and held it in 1 quarter. The position peaked at $291K in Q3 2015. 85 funds tracked by Wall St. Rank hold ATRA as of Q4 2015.

Yale University reported no remaining Atara Biotherapeutics position as of Q4 2015 after selling out during the quarter.
Yale University sold 370 Atara Biotherapeutics shares in Q4 2015, an estimated $291K.
Yale University first reported a position in Atara Biotherapeutics in Q3 2015 and held it in 1 quarter.
Yale University's Atara Biotherapeutics position peaked at $291K in Q3 2015.
85 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2015.

Based on Yale University's 13F filing for Q4 2015, filed 11 Feb 2016.